logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics presents ovarian cancer study at conference

Kazia has presented at the annual Congress of the European Society for Medical Oncology (ESMO), held in Barcelona.

Kazia Therapeutics Ltd - Kazia Therapeutics presents ovarian cancer study at conference
The conference runs from 27 September to 1 October 2019

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has released additional data from its ongoing phase I study of Cantrixil in ovarian cancer in the form a poster presentation.

The poster which was presented at the ESMO conference included data from all nine patients in the dose escalation part of the study (Part A).

Two of the nine patients or 22% were considered to have achieved a ‘partial response’ to Cantrixil therapy and three further patients were evaluated as ‘stable disease’.

Notably, the median progression-free survival for all patients in Part A was calculated to be 5.5 months compared to historical controls in a similarly advanced population of 3.4 months.

This suggests Cantrixil may help to delay tumour recurrence.

Cantrixil is currently being developed for treatment of ovarian cancer and is being trialled in hospitals across Australia and the US under an Investigational New Drug application which was approved by the US FDA in 2016.

The drug is active

Kazia’s CEO Dr James Garner added: “It is terrific to see further very promising data emerging from the Cantrixil phase I study.

“Put simply, the drug is active. The expansion cohort, which is currently in progress, will help us to further quantify and substantiate that activity.

“In parallel, we continue to discuss the program with clinicians, potential partners, and investors, as we consider how best to take Cantrixil forward after completion of the phase I study.”

Part B data expected in 2020

Part B of the study completed the recruitment of 12 patients at the maximum tolerated dose (MTD) in August 2019 to seek preliminary signals of efficacy.

Kazia expects to report data from this component of the study early in calendar 2020.

Patients showing evidence of clinical response

Australian lead investigator for the study, Associate Professor Jim Coward said: “We have made excellent progress with the Cantrixil study.

“We are seeing several patients now with potential evidence of clinical response. Interestingly, some early signs are emerging that the drug may help to reverse chemotherapy resistance, supporting the preclinical data that was originally collected at Yale.

“The expansion cohort is fully recruited, and my colleagues and I look forward to seeing further data in due course.”

Quick facts: Kazia Therapeutics Ltd

Price: 0.57 AUD

ASX:KZA
Market: ASX
Market Cap: $35.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Kazia Therapeutics releases data from study of GDC-0084 into...

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer Dr James Garner updates Proactive on the release of positive key interim data from the company's ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. Dr Garner explains...

on 11/24/2019

2 min read